How Often Do Sensitivity Analyses for Economic Parameters Change Cost-Utility Analysis Conclusions?
Author InfoBruce R. Schackman (Division of Outcomes and Effectiveness Research, Department of Public Health, Weill Medical College of Cornell University, New York, USA) Heather Taffet Gold (Division of Outcomes and Effectiveness Research, Department of Public Health, Weill Medical College of Cornell University, New York, USA) Patricia W. Stone (Columbia University, School of Nursing, New York, USA) Peter J. Neumann (Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, USA) Abstract Background: There is limited evidence about the extent to which sensitivity analysis has been used in the cost-effectiveness literature. Sensitivity analyses for health-related QOL (HR-QOL), cost and discount rate economic parameters are of particular interest because they measure the effects of methodological and estimation uncertainties. Aim: To investigate the use of sensitivity analyses in the pharmaceutical cost-utility literature i
